TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Allergen Challenge
Brief Summary: Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Biological: IMA-638 is a biologic | Intervention Type: BIOLOGICAL; Name: IMA-638 is a biologic; Assigned to Arm(s): 1
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
C: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: OCS (prednisone/prednisolone) | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: OCS (prednisone/prednisolone); Assigned to Arm(s): Mepolizumab, Placebo
D: Arm Label: Arm Mepolizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab 100mg | Arm Label: Arm Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Mepolizumab 100mg, Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Mepolizumab 100mg; Assigned to Arm(s): Arm Mepolizumab 100 mg, Arm Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Allergen Challenge
Brief Summary: Primary purpose of the protocol is to determine if IMA-638 prevents a mild asthma attack by a subject with mild asthma inhaling an allergen.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Biological: IMA-638 is a biologic | Intervention Type: BIOLOGICAL; Name: IMA-638 is a biologic; Assigned to Arm(s): 1
B: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)
C: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare a specific fear-reducing information with symptom-based exercise


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General health talk, Behavioral: Handout of The Back Book, Behavioral: Back exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Handout of The Back Book, Behavioral: Back exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Back exercise | Intervention Type: BEHAVIORAL; Name: General health talk; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Handout of The Back Book; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Back exercise; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: BEHAVIORAL; Name: Fear-reducing Information; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Symptom-based exercise; Assigned to Arm(s): N/A
C: Arm Label: RESTORE Intervention; Type: EXPERIMENTAL; Interventions: Other: RESTORE Intervention | Arm Label: Control Group 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: RESTORE Intervention; Assigned to Arm(s): RESTORE Intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Chiropractic Manual treatment + home exercise (procedure+behavior) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Supervised rehabilitative exercise+home exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home exercise | Intervention Type: PROCEDURE; Name: Chiropractic Manual treatment + home exercise (procedure+behavior); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Supervised rehabilitative exercise+home exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Home exercise; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare a specific fear-reducing information with symptom-based exercise


Options:
A: Intervention Type: DEVICE; Name: Total Disc Prosthesis; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Multidisciplinary rehabilitation program; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Fear-reducing Information; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Symptom-based exercise; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Mod. functional restoration-Individ. dynamic back-muscle; Assigned to Arm(s): N/A
D: Arm Label: Assistance with Pain Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Assistance with Pain treatment | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assistance with Pain treatment; Assigned to Arm(s): Assistance with Pain Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.


Options:
A: Arm Label: Placebo plus SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 4 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 4 mg/kg | Arm Label: Belimumab 10 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus SOC | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 4 mg/kg; Assigned to Arm(s): Belimumab 4 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus SOC
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
D: Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 10 mg/kg | Intervention Type: BIOLOGICAL; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: BIOLOGICAL; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Brief Summary: The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied


Options:
A: Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Open Label; Type: OTHER; Interventions: Drug: Anti-IP-10 Antibody | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction, Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 1: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Open Label
B: Arm Label: rhuMAb Beta7; Type: EXPERIMENTAL; Interventions: Drug: rhuMAb Beta7 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: rhuMAb Beta7; Assigned to Arm(s): rhuMAb Beta7
C: Arm Label: Abatacept (ABA); Type: EXPERIMENTAL; Interventions: Drug: abatacept (ABA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: abatacept; Type: OTHER; Interventions: Drug: abatacept | Intervention Type: DRUG; Name: abatacept (ABA); Assigned to Arm(s): Abatacept (ABA) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): abatacept
D: Arm Label: Asacol 2.4 g/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg (mesalamine) | Arm Label: Asacol 4.8 g/day; Type: EXPERIMENTAL; Interventions: Drug: Asacol 800 mg (mesalamine) | Intervention Type: DRUG; Name: Asacol 800 mg (mesalamine); Assigned to Arm(s): Asacol 4.8 g/day | Intervention Type: DRUG; Name: Asacol 400 mg (mesalamine); Assigned to Arm(s): Asacol 2.4 g/day

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Repeated-Dose Evaluation of Analgesic Use and Safety of Dilaudid SR (Hydromorphone HCI) in Patients With Chronic Non-Malignant Pain
Brief Summary: The purpose of this repeated dose study is to develop recommended dosing information for initiation of therapy with OROS Hydromorphone in patients with chronic non-malignant pain converting from other strong oral or transdermal opioids. It will also assist in the development of a recommended starting dose by which patients can be titrated to an appropriate maintenance dose of OROS Hydromorphone HCI. The safety profile for OROS Hydromorphone HCI will also be evaluated.


Options:
A: Intervention Type: DRUG; Name: Oxymorphone Extended Release; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: CG 5503;tapentadol; Assigned to Arm(s): N/A
C: Arm Label: Double-blind BTDS 10 or 20; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine transdermal system | Arm Label: Double-blind Placebo TDS; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buprenorphine transdermal system; Assigned to Arm(s): Double-blind BTDS 10 or 20 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo TDS
D: Intervention Type: DRUG; Name: OROS Hydromorphone HCI; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma
Brief Summary: Primary:

* To demonstrate that capecitabine/oxaliplatin as adjuvant chemotherapy is superior to observation alone in terms of 3 year disease-free survival (DFS) rate in chemotherapy-naïve patients who underwent potentially curative resection for gastric cancer.

Secondary:

* To compare the overall survival of surgery and capecitabine/ oxaliplatin as adjuvant therapy versus surgery alone. To evaluate the safety profile of capecitabine/oxaliplatin adjuvant therapy.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1
B: Arm Label: S-1 plus cisplatin; Type: EXPERIMENTAL; Interventions: Drug: s-1 plus cisplatin | Arm Label: 5-Fu plus cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fu plus cisplatin | Intervention Type: DRUG; Name: s-1 plus cisplatin; Assigned to Arm(s): S-1 plus cisplatin | Intervention Type: DRUG; Name: 5-Fu plus cisplatin; Assigned to Arm(s): 5-Fu plus cisplatin
C: Arm Label: FLOT; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Drug: Leucovorin, Drug: Oxaliplatin, Drug: Docetaxel | Arm Label: ECF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Cisplatin, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ECF | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): ECF | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): ECF
D: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Everolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex
Brief Summary: The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma)

The hypothesis is that the drug will cause the tumor size to decrease, and may have beneficial activity separate from effects on tumors in patients.


Options:
A: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 0.1 % Rapamycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rapamycin | Arm Label: 1% Rapamycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): 0.1 % Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): 1% Rapamycin
C: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Everolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex
Brief Summary: The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma)

The hypothesis is that the drug will cause the tumor size to decrease, and may have beneficial activity separate from effects on tumors in patients.


Options:
A: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A
B: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
C: Intervention Type: DRUG; Name: Rapamycin, sirolimus; Assigned to Arm(s): N/A
D: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Dose-escalating Study of the Safety and Pharmacokinetics of GSK679586A in Healthy Volunteers and Mild Asthmatics.
Brief Summary: This is a two part study. Part I is designed to test single doses of GSK678586A in healthy volunteers. Part II is designed to test repeat doses (two doses) of GSK679586A in patients with mild asthma. Both parts are designed to investigate the safety, tolerability and the way the body absorbs GSK679586A when given by intravenous infusion (through a vein in your arm).


Options:
A: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab 300 mg, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Placebo matching OCS capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching mepolizumab, Drug: Active OCS capsules (5 mg prednisolone or prednisone), Drug: Placebo matching OCS capsules | Intervention Type: DRUG; Name: Mepolizumab 300 mg; Assigned to Arm(s): Mepolizumab | Intervention Type: DRUG; Name: Placebo matching mepolizumab; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Active OCS capsules (5 mg prednisolone or prednisone); Assigned to Arm(s): Mepolizumab, Placebo | Intervention Type: DRUG; Name: Placebo matching OCS capsules; Assigned to Arm(s): Mepolizumab, Placebo
D: Arm Label: Mepolizumab 750mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 750 | Arm Label: Mepolizumab 250mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 250 | Arm Label: Mepolizumab 75mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 75 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo saline | Intervention Type: BIOLOGICAL; Name: Mepolizumab 750; Assigned to Arm(s): Mepolizumab 750mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 250; Assigned to Arm(s): Mepolizumab 250mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 75; Assigned to Arm(s): Mepolizumab 75mg | Intervention Type: DRUG; Name: Placebo saline; Assigned to Arm(s): Placebo

Answer: B